Novel chimeric monoclonal antibodies that block fentanyl effects and alter fentanyl biodistribution in mice.

ABSTRACT: The prevalence and societal impact of opioid use disorder (OUD) is an acknowledged public health crisis that is further aggravated by the current pandemic. One of the devastating consequences of OUD is opioid overdose deaths. While multiple medications are now available to treat OUD, given the prevalence and societal burden, additional well-tolerated and effective therapies are still needed. To this point, we have developed chimeric monoclonal antibodies (mAb) that will specifically complex with fentanyl and its analogs in the periphery, thereby preventing them from reaching the central nervous system. Additionally, mAb-based passive immunotherapy offers a high degree of specificity to drugs of abuse and does not interfere with an individual's ability to use any of the medications used to

SUBMITTER: Ban B 

PROVIDER: S-EPMC8547829 | biostudies-literature | 2021 Jan-Dec

REPOSITORIES: biostudies-literature